SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) announces that the Company will be presenting a webcast providing an investor presentation, corporate update and review of its ongoing business strategies and plans. The webcast will be presented following the close of market today at 4:30 PM (Eastern Time) and can be accessed at http://www.investorcalendar.com/IC/CEPage.asp?ID=138418 at that time. The webcast will also be accessible for the following thirty days via the Investors section at "Calendar of Events" on the Company's website at http://www.cardiumthx.com.
Forward-Looking Statements in Webcast
Except for statements of historical fact, the matters discussed in the webcast are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. Actual results may also differ substantially from those described in or contemplated by the webcast due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties inherent in the conduct of human clinical trials, including the timing, costs and results of such trials, our limited experience in the development, testing and marketing of therapeutic hypothermia devices, uncertainties regarding potential corporate development partners, our dependence upon proprietary technology, uncertainties regarding ongoing needs to support product development programs and other cash expenditures, our history of operating losses and accumulated deficits, risks and uncertainties related to our ability to raise cash under difficult capital market conditions, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.
Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium
Therapeutics, Inc. Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM) are
trademarks of Tissue Repair Company. InnerCool Therapies(R), InnerCool(R), Celsius Control System(R), RapidBlue(TM), CoolBlue(TM), Accutrol(R), Temperature Control Element(R), TCE(R) and UroCool(TM) are trademarks of InnerCool Therapies, Inc.
|SOURCE Cardium Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved